| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/27/2013 | CN102940648A Bee propolis soft capsule and manufacturing process thereof |
| 02/27/2013 | CN102940639A Application of indometacin2-aryl morpholine ethyl ester in preparing medicine capable of resisting breast cancer |
| 02/27/2013 | CN102940635A Breast cancer resistant application of indenoisoquinoline vascular endothelial cell growth factor-2 receptor antagonist |
| 02/27/2013 | CN102940630A Medicinal composition containing temsirolimus and preparation method of medicinal composition |
| 02/27/2013 | CN102940608A Tripterine controlled-release solid dispersion |
| 02/27/2013 | CN102940606A Flammulina velutipe sterol extract liposome preparation and preparation method thereof |
| 02/27/2013 | CN102382825B Human miR-1826 antisense nucleic acid and application thereof |
| 02/27/2013 | CN102373206B PPP2R5C-siRNA799 for targeted inhabitation of PPP2R5C gene expression and tumor T cell multiplication and application thereof |
| 02/27/2013 | CN102351859B Antibiotic Pseudonocardian A and Pseudonocardian B, its preparation method thereof and its application in preparation of antibiotics and antitumor drug |
| 02/27/2013 | CN102302450B Hydrophobic drug-albumin-glucan nano emulsion, as well as preparation method and application thereof |
| 02/27/2013 | CN102198117B Thermosensitive polymeric microcapsules and preparation method and use thereof |
| 02/27/2013 | CN102178796B Application of active ingredients of juncus effuses in preparation of medicaments for resisting tumors or inhibiting angiogenesis, health-care food or cosmetics |
| 02/27/2013 | CN102168119B Method for preparing diaporthein B and application of diaporthein B to preparation of antitumor medicaments |
| 02/27/2013 | CN102144981B Gemcitabine hydrochloride lyophilized powder injection and preparation method thereof |
| 02/27/2013 | CN102134188B Tetrahydroanthraquinone compound Prisconnatacin and preparation method and application thereof in preparation of anti-tumor medicaments |
| 02/27/2013 | CN102101878B Hellebore petunidin space isomer compound and preparation and application thereof |
| 02/27/2013 | CN102100736B Method for simultaneously extracting water-soluble and lipid-soluble effective components in traditional Chinese medicine salvia miltiorrhiza bunge |
| 02/27/2013 | CN102080083B Human miR-149 antisense nucleotide and application thereof |
| 02/27/2013 | CN102002035B Delta and epsilon crystal forms of imatinib mesylate |
| 02/27/2013 | CN101959884B Derivatives of 6-heterocyclic-imidazo[l,2-alpha]pyrroine-2-carboxamides, preparation thereof and therapeutic application thereof |
| 02/27/2013 | CN101757560B Medicament for treating liver cancer and preparation method thereof |
| 02/27/2013 | CN101665527B Ginsenoside, preparation method thereof and use thereof |
| 02/27/2013 | CN101622229B Novel pyrrole derivative having ureido group and aminocarbonyl group as substituents |
| 02/27/2013 | CN101522683B Pyraz0l0(l,5-A) (1, 3, 5) triazine and pyrazolo (1, 5-A) pyrimidine derivatives useful as protein kinase inhibitors |
| 02/27/2013 | CN101475513B Raf and HDAC small molecular double inhibitor, and preparation and use thereof |
| 02/27/2013 | CN101389628B Indolopyridines as EG5 kinesin modulators |
| 02/27/2013 | CN101265249B 4-position carbonyl nitrogen-containing derivative of 6-methoxy-4',7-dihydroxyisoflavone and medical use thereof |
| 02/27/2013 | CN101010102B Composition comprising non-oxidizable fatty acid analogoues and plant and/or fish oils |
| 02/26/2013 | US8383812 N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes |
| 02/26/2013 | US8383799 Translocation and mutant ROS kinase in human non-small cell lung carcinoma |
| 02/26/2013 | US8383675 Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications |
| 02/26/2013 | US8383665 Immunomodulatory compositions |
| 02/26/2013 | US8383636 Acyclic amine inhibitors of 5-methytioadenosine phosphorylase and nucleosidase |
| 02/26/2013 | US8383618 C2-fluoro substituted piperazine linked pyrrolo[2,1-C][1,4] benzodiazepine dimers and a process for the preparation thereof |
| 02/26/2013 | US8383609 Phosphorus containing heterocyclic compounds, sugar analogues, and compositions having anti-cancer activity containing the same |
| 02/26/2013 | US8383358 Use of 2 anti-SPARC antibodies to predict response to melanoma chemotherapy |
| 02/26/2013 | US8383153 Poly(amidoamine) oligomer hydrogel for drug delivery and drug carrier using the same |
| 02/26/2013 | US8383129 Employment of rotavirus proteins, derived proteins and peptides for the modulation of tissue permeability |
| 02/26/2013 | US8383117 CD44E tumor specific antibody |
| 02/26/2013 | US8383086 Nicotinamide riboside kinase compositions and methods for using the same |
| 02/26/2013 | CA2655668C Aziridinyl-epothilone compounds |
| 02/26/2013 | CA2537336C Multi-arm polymer prodrugs |
| 02/26/2013 | CA2536256C Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ed-b |
| 02/26/2013 | CA2523426C Aza spiro alkane derivatives as inhibitors of metalloproteases |
| 02/26/2013 | CA2327586C Fap.alpha.-specific antibody with improved producibility |
| 02/21/2013 | WO2013026059A1 Inhibition of oncogenic kras-induced gm-csf production and function |
| 02/21/2013 | WO2013026025A1 Cyclohexyl azetidine derivatives as jak inhibitors |
| 02/21/2013 | WO2013026015A1 Muc1 ligand traps for use in treating cancers |
| 02/21/2013 | WO2013025972A1 Yeast-muc1 immunotherapeutic compositions and uses thereof |
| 02/21/2013 | WO2013025944A1 Inhibition of angiogenesis in refractory tumors |
| 02/21/2013 | WO2013025939A2 Compounds and methods for treating cancer by inhibiting the urokinase receptor |
| 02/21/2013 | WO2013025925A1 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
| 02/21/2013 | WO2013025882A2 Tricyclic compounds as anticancer agents |
| 02/21/2013 | WO2013025853A1 Neuregulin antibodies and uses thereof |
| 02/21/2013 | WO2013025733A1 Lysophosphatidic acid receptor antagonists |
| 02/21/2013 | WO2013025479A1 Jaml specific binding agents, antibodies, and uses related thereto |
| 02/21/2013 | WO2013025467A2 Methods of treating hematological proliferative disorders by targeting epha3 expressed on aberrant vasculature in bone marrow |
| 02/21/2013 | WO2013025446A2 Anti-fzd10 monoclonal antibodies and methods for their use |
| 02/21/2013 | WO2013025418A1 Delivery system for specifically targeting cancer cells and method of use thereof |
| 02/21/2013 | WO2013025337A1 Cyclodextrin-based polymers for therapeutic delivery |
| 02/21/2013 | WO2013025074A2 Anticancer or antioxidant composition containing quamoclit pennata extract or compound derived from quamoclit pennata extract |
| 02/21/2013 | WO2013025064A2 Anti-cancer composition comprising wnt decoy receptors |
| 02/21/2013 | WO2013025004A2 Pharmaceutical composition for preventing or treating cancer comprising radix lithospermi seu arnebiae extract as an active ingredient |
| 02/21/2013 | WO2013024898A1 Heterocyclic derivative and pharmaceutical drug |
| 02/21/2013 | WO2013024865A1 Antitumor agent and therapeutic effect prediction method for patients with kras-mutated colorectal cancer |
| 02/21/2013 | WO2013024582A1 Mphosph1 peptides and vaccines including the same |
| 02/21/2013 | WO2013024495A1 Pharmaceutical formulations of cabazitaxel |
| 02/21/2013 | WO2013024447A1 Compounds for use in cancer therapy |
| 02/21/2013 | WO2013024324A1 [Cu(thp)4]n[X]-n COMPOUNDS FOR THE TREATMENT OF A BROAD RANGE OF HUMAN SOLID TUMORS, INCLUDING REFRACTORY TUMORS |
| 02/21/2013 | WO2013024320A1 2, 6 xylidine derivatives for the treatment of pain |
| 02/21/2013 | WO2013024282A2 Compounds and their uses |
| 02/21/2013 | WO2013024035A1 Folate conjugates of albumin-binding entities |
| 02/21/2013 | WO2013024002A1 PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE |
| 02/21/2013 | WO2013023622A1 Acylated derivative of homoharringtonine, preparation method therefor, and application thereof |
| 02/21/2013 | WO2013023620A1 Aminated derivative of homoharringtonine, preparation method therefor, and application thereof |
| 02/21/2013 | WO2013023557A1 Humanized monoclone antibody of macrophage inhibition factor 1 and use thereof |
| 02/21/2013 | WO2013023442A1 Pharmaceutical application of peptide of soft-shell turtle |
| 02/21/2013 | WO2013023361A1 Uses of human zfx gene and related drugs thereof |
| 02/21/2013 | WO2013023300A1 Inhibitors of androgen receptor activation function-2 (af2) as therapeutics and methods for their use |
| 02/21/2013 | WO2013023274A1 Substituted 2-imidazolidinones and 2-imidazolones and their use in the treatment of cancer |
| 02/21/2013 | WO2013023273A1 Piperazine derivatives |
| 02/21/2013 | WO2012176163A3 Compounds for the treatment of cancers associated with human papillomavirus |
| 02/21/2013 | WO2012174549A9 Blockade of eosinophil production by toll-like receptors |
| 02/21/2013 | WO2012174028A3 Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion |
| 02/21/2013 | WO2012135517A3 Preparation of maytansinoid antibody conjugates by a one-step process |
| 02/21/2013 | WO2012116073A3 Amphiphilic dendron-coils, micelles thereof and uses |
| 02/21/2013 | WO2012112792A3 Multicomponent compositions and their uses |
| 02/21/2013 | WO2012090204A8 2 - (2 - phenylethenyl) - 1, 3 -benzothiazine derivatives useful for the treatment of cancer |
| 02/21/2013 | WO2012065139A3 Entpd5 inhibitors |
| 02/21/2013 | WO2011116954A8 Prophylaxis of colorectal and gastrointestinal cancer |
| 02/21/2013 | WO2011101069A3 1, 8 -naphthyridines as kinase inhibitors |
| 02/21/2013 | US20130046077 Dolastatin 15 derivatives |
| 02/21/2013 | US20130046020 Eicosapentaenoic acid concentrate |
| 02/21/2013 | US20130046019 Methods of Treatment Using 3-Bromopyruvate and Other Selective Inhibitors of ATP Production |
| 02/21/2013 | US20130046010 Sumo as a marker of cancer development and target for cancer therapy |
| 02/21/2013 | US20130046009 Rho kinase inhibitors for treatment of mastocytosis and acute myeloid leukemia |
| 02/21/2013 | US20130046007 Selective reduction of allelic variants |
| 02/21/2013 | US20130045997 Pirfenidone therapy and inducers of of cytochrome p450 |
| 02/21/2013 | US20130045993 Inhibitors of cyclin-dependent kinases and their use |
| 02/21/2013 | US20130045983 Hsp90 inhibitors for therapeutic treatment |